ICML 2023 | Hodgkin lymphoma: prognostic markers in the era of novel treatments
Sanjal Desai
• 19 Jun 2023
Sanjal Desai, MBBS, University of Minnesota, Minneapolis, MN, describes prognostic markers used in Hodgkin lymphoma (HL) to predict patient outcomes. Traditional prognostic markers are used in the frontline and relapsed settings, however some prognostic effects are compensated for when novel treatments are used. Dr Desai discusses the need for better prognostic markers to predict a patient’s response to novel therapies. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
